Kymera Therapeutics, Inc. (KYMR) Reports Q1 Loss, Tops Revenue Estimates

Financial Performance - Kymera Therapeutics reported a quarterly loss of $0.82 per share, better than the Zacks Consensus Estimate of a loss of $0.92, but worse than a loss of $0.69 per share a year ago, indicating an earnings surprise of 10.87% [1] - The company posted revenues of $22.1 million for the quarter ended March 2025, surpassing the Zacks Consensus Estimate by 123.59%, compared to revenues of $10.29 million in the same quarter last year [2] - Over the last four quarters, Kymera has surpassed consensus EPS estimates three times and topped consensus revenue estimates two times [2] Stock Performance - Kymera Therapeutics shares have declined approximately 23.5% since the beginning of the year, contrasting with the S&P 500's decline of 3.7% [3] - The current consensus EPS estimate for the upcoming quarter is -$0.95 on revenues of $10.21 million, and for the current fiscal year, it is -$3.76 on revenues of $51.08 million [7] Industry Outlook - The Medical - Biomedical and Genetics industry, to which Kymera belongs, is currently ranked in the top 32% of over 250 Zacks industries, suggesting a favorable outlook compared to the bottom 50% [8] - Empirical research indicates a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can impact Kymera's stock performance [5]